FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029402380> ?p ?o ?g. }

• W2029402380 endingPage "806" @default.
• W2029402380 startingPage "801" @default.
• W2029402380 abstract "Oral topotecan (Hycamtin(®)) has been recently approved for the treatment of relapsed small cell lung cancer (SCLC) in 2007, however, the bioavailability and pharmacokinetic data of topotecan for Chinese patients is still limited. Xinze(®) is a new and the only capsule formulation of topotecan used in China that is similar to Hycamtin(®). The current study aimed to investigate the absolute bioavailability and pharmacokinetics of Xinze(®) in Chinese patients with advanced cancers. On day 1, an IV dose of 1.5 mg/m(2)/d as a 30 min continuous infusion was administered. Patients took the oral topotecan at one of two dose levels: 1.5 mg/m(2)/d (six patients) or 1.9 mg/m(2)/d (seven patients) on day 2. Plasma pharmacokinetics of total topotecan and topotecan in the lactone form were performed on both days using ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Single-nucleotide polymorphisms (SNPs) identified in exon 5 (421C>A) and in exon 2 (34G>A) in ATP-binding cassette sub-family G member 2 (ABCG2) were analyzed by direct sequencing. Safety assessments were performed throughout the study. The maximum plasma concentration (Cmax) reached at 1-2 h and the elimination half-life time (T1/2) was approximately 4.2 h after oral administration. The absolute bioavailability of total topotecan in the 1.5 mg/m(2)/d and 1.9 mg/m(2)/d groups averaged 41.23 ± 11.8% and 36.00 ± 14.8%, respectively. The patients with heterozygous SNPs had essentially the same bioavailability and pharmacokinetics. The bioavailability of topotecan after oral administration illustrates good systemic exposure at dosages of 1.5 mg/m(2)/d and 1.9 mg/m(2)/d over a five-day schedule in Chinese patients. On a dose-normalized basis, the values of Cmax and AUC0-t for total topotecan in Chinese patients were higher than in Caucasians following oral and intravenous administration, while the T1/2 was consistent." @default.
• W2029402380 created "2016-06-24" @default.
• W2029402380 creator A5006901857 @default.
• W2029402380 creator A5008382997 @default.
• W2029402380 creator A5009035703 @default.
• W2029402380 creator A5026045028 @default.
• W2029402380 creator A5031769614 @default.
• W2029402380 creator A5031810848 @default.
• W2029402380 creator A5036188864 @default.
• W2029402380 creator A5053708169 @default.
• W2029402380 creator A5060532655 @default.
• W2029402380 creator A5062168574 @default.
• W2029402380 creator A5083147929 @default.
• W2029402380 date "2013-10-01" @default.
• W2029402380 modified "2023-10-16" @default.
• W2029402380 title "Oral topotecan: Bioavailability, pharmacokinetics and impact of ABCG2 genotyping in Chinese patients with advanced cancers" @default.
• W2029402380 cites W1579959111 @default.
• W2029402380 cites W1859729923 @default.
• W2029402380 cites W2001323352 @default.
• W2029402380 cites W2001615357 @default.
• W2029402380 cites W2010091839 @default.
• W2029402380 cites W2020713814 @default.
• W2029402380 cites W2023555639 @default.
• W2029402380 cites W2051835394 @default.
• W2029402380 cites W2066933615 @default.
• W2029402380 cites W2084378161 @default.
• W2029402380 cites W2085274398 @default.
• W2029402380 cites W2091025801 @default.
• W2029402380 cites W2092998745 @default.
• W2029402380 cites W2093011419 @default.
• W2029402380 cites W2099333512 @default.
• W2029402380 cites W2117150909 @default.
• W2029402380 cites W2158127925 @default.
• W2029402380 cites W2168756497 @default.
• W2029402380 cites W2172097735 @default.
• W2029402380 doi "https://doi.org/10.1016/j.biopha.2013.08.002" @default.
• W2029402380 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24074809" @default.
• W2029402380 hasPublicationYear "2013" @default.
• W2029402380 type Work @default.
• W2029402380 sameAs 2029402380 @default.
• W2029402380 citedByCount "7" @default.
• W2029402380 countsByYear W20294023802016 @default.
• W2029402380 countsByYear W20294023802018 @default.
• W2029402380 countsByYear W20294023802021 @default.
• W2029402380 countsByYear W20294023802022 @default.
• W2029402380 crossrefType "journal-article" @default.
• W2029402380 hasAuthorship W2029402380A5006901857 @default.
• W2029402380 hasAuthorship W2029402380A5008382997 @default.
• W2029402380 hasAuthorship W2029402380A5009035703 @default.
• W2029402380 hasAuthorship W2029402380A5026045028 @default.
• W2029402380 hasAuthorship W2029402380A5031769614 @default.
• W2029402380 hasAuthorship W2029402380A5031810848 @default.
• W2029402380 hasAuthorship W2029402380A5036188864 @default.
• W2029402380 hasAuthorship W2029402380A5053708169 @default.
• W2029402380 hasAuthorship W2029402380A5060532655 @default.
• W2029402380 hasAuthorship W2029402380A5062168574 @default.
• W2029402380 hasAuthorship W2029402380A5083147929 @default.
• W2029402380 hasConcept C104317684 @default.
• W2029402380 hasConcept C112705442 @default.
• W2029402380 hasConcept C126322002 @default.
• W2029402380 hasConcept C149011108 @default.
• W2029402380 hasConcept C181389837 @default.
• W2029402380 hasConcept C185592680 @default.
• W2029402380 hasConcept C22979827 @default.
• W2029402380 hasConcept C2776694085 @default.
• W2029402380 hasConcept C2781209748 @default.
• W2029402380 hasConcept C44312359 @default.
• W2029402380 hasConcept C512196 @default.
• W2029402380 hasConcept C55493867 @default.
• W2029402380 hasConcept C71924100 @default.
• W2029402380 hasConcept C98274493 @default.
• W2029402380 hasConceptScore W2029402380C104317684 @default.
• W2029402380 hasConceptScore W2029402380C112705442 @default.
• W2029402380 hasConceptScore W2029402380C126322002 @default.
• W2029402380 hasConceptScore W2029402380C149011108 @default.
• W2029402380 hasConceptScore W2029402380C181389837 @default.
• W2029402380 hasConceptScore W2029402380C185592680 @default.
• W2029402380 hasConceptScore W2029402380C22979827 @default.
• W2029402380 hasConceptScore W2029402380C2776694085 @default.
• W2029402380 hasConceptScore W2029402380C2781209748 @default.
• W2029402380 hasConceptScore W2029402380C44312359 @default.
• W2029402380 hasConceptScore W2029402380C512196 @default.
• W2029402380 hasConceptScore W2029402380C55493867 @default.
• W2029402380 hasConceptScore W2029402380C71924100 @default.
• W2029402380 hasConceptScore W2029402380C98274493 @default.
• W2029402380 hasIssue "8" @default.
• W2029402380 hasLocation W20294023801 @default.
• W2029402380 hasLocation W20294023802 @default.
• W2029402380 hasOpenAccess W2029402380 @default.
• W2029402380 hasPrimaryLocation W20294023801 @default.
• W2029402380 hasRelatedWork W1969574919 @default.
• W2029402380 hasRelatedWork W2029402380 @default.
• W2029402380 hasRelatedWork W2068318921 @default.
• W2029402380 hasRelatedWork W2069936009 @default.
• W2029402380 hasRelatedWork W2080955156 @default.
• W2029402380 hasRelatedWork W2092998745 @default.
• W2029402380 hasRelatedWork W2297740383 @default.
• W2029402380 hasRelatedWork W2373237830 @default.

• next